Mangoceuticals faces an existential liquidity crisis characterized by a 25.96% year-over-year revenue decline and deeply negative operating margins that reached -46.1% in 2026Q1.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest May 19, 2026 | -$0.22 vs — | $67,864 vs — |
Q2 2026 Apr 1, 2026 | $0.13 vs — | $94,360 vs — |
Q4 2025 Nov 14, 2025 | -$0.69 vs — | $84,246 vs — |
Q3 2025 Aug 14, 2025 | -$0.57 vs — | $168,109 vs — |
Quest Diagnostics (NYSE: DGX - Get Free Report) and Mangoceuticals (NASDAQ: MGRX - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation. Analyst Recommendations This is a summary of recent ratings
What happened Mangoceuticals, Inc. (NASDAQ: MGRX) closed a registered direct offering on October 9, 2026 for about $492,750. The company sold 657,000 shares of common stock together with 657,000 warrants at $0.75 per unit, and the unit price was about 74% above the referenced $0.43 close. Each warrant can buy one share at $1.00, becomes
Transaction follows a $2. 5 million strategic investment commitment at MangoRx IP Holdings to support intellectual property commercialization DALLAS, TX, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing and selling health and wellness products through its telemedicine platforms under the MangoRx and PeachesRx brands, today announced the closing of a registered direct offering with a U.
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Friday.
Benchmark MGRX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Mangoceuticals, Inc. (MGRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.19 | $3.31M | -0.22 | -25.96% | -4791.48% | -106.13% | — | |
| $26.00 | $5.8B | -42.42 | 59% | -5.51% | -30.03% | — | |
| $11.91 | $202.57M | -3.56 | -1.98% | -27.03% | -24.11% | — | |
| $8.77 | $1.58B | -10.30 | -1.54% | -6.27% | -11.63% | — | |
| $8.76 | $164.38M | 35.77 | 18.78% | 4.66% | 3.6% | — | |
| $245.01 | $176.55B | 126.51 | 35.82% | 10.67% | 3.15% | 1.13% |
Mangoceuticals, Inc. (MGRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Mangoceuticals, Inc. (MGRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 21, 2026·SEC
Aug 4, 2026·SEC
Jul 30, 2026·SEC
Get notified when MGRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Mangoceuticals, Inc. (MGRX) stock FAQ — growth, dividends, profitability & financials explained
Mangoceuticals, Inc. (MGRX) reported $0.3M in revenue over the trailing twelve months. Revenue was $0.5M in fiscal year 2025.
Mangoceuticals, Inc. (MGRX) revenue fell by 38.9% over the trailing twelve months, compared with the twelve months before.
No. Mangoceuticals, Inc. (MGRX) reported a net loss of $15.1M over the trailing twelve months.
Mangoceuticals, Inc. (MGRX) had a return on equity (ROE) of -106.1% over the trailing twelve months. A negative ROE means the company lost money over the period.
Mangoceuticals, Inc. (MGRX) had negative free cash flow of $3.9M over the trailing twelve months.
